| Literature DB >> 30698348 |
Takanari Wakayama1,2, Yuki Ito1, Kiyoshi Sakai1,2, Mio Miyake1, Eiji Shibata3, Hiroyuki Ohno2, Michihiro Kamijima1.
Abstract
OBJECTIVES: 2-Ethyl-1-hexanol (2EH), a fragrance ingredient and a raw material for the production of plasticizer di(2-ethylhexyl) phthalate, is responsible for sick building syndrome (SBS). This review aims to clarify the 2EH characteristics as an indoor air pollutant such as indoor air concentration, emission mechanism, toxicity, and clinical effects.Entities:
Keywords: 2-ethyl-1-hexanol; emission mechanism; indoor air pollution; indoor concentration; sick building syndrome; volatile organic compounds
Mesh:
Substances:
Year: 2019 PMID: 30698348 PMCID: PMC6499367 DOI: 10.1002/1348-9585.12017
Source DB: PubMed Journal: J Occup Health ISSN: 1341-9145 Impact factor: 2.708
The physical and chemical properties of 2EH
| Property | Value | Reference |
|---|---|---|
| Molecular formula | ‐ | |
| Structure formula |
| ‐ |
| CAS No. | 104‐76‐7 | ‐ |
| Molecular weight | 130.23 g/mol | ‐ |
| Physical form | Colorless, oily liquid with mild, sweat, and slightly floral‐rosy odor |
|
| Melting point | ‐75°C |
|
| Boiling point | 188.52°C |
|
| Density at 20°C | 0.834 g/cm3 |
|
| Vapor density | 4.49 g/cm3 |
|
| Vapor pressure | 0.06 mmHg at 20°C, 0.185 mmHg at 25°C |
|
| Solubility | Soluble in organic solvents |
|
| Solubility in water | 880 mg/L at 25°C, 1000 mg/L at 20°C |
|
| Odor threshold | 0.075 ppm (perception), 0.138 ppm (100% recognition) |
|
| Conversion factors for vapor (25°C 1013 hPa) | 1 ppm = 5.32 mg/m3 |
|
Figure 1The emission mechanism of 2‐Ethyl‐1‐hexanol (2EH) by a hydrolysis reaction. Compounds having 2‐ethylhexyl group contained in floor materials and adhesives are hydrolyzed by the alkaline moisture content in concrete. For example, DEHP contained in PVC flooring is hydrolyzed, emitting 2EH into the room18
Summary of indoor air concentration of 2‐Ethyl‐1‐hexanol
| Country | Location | Study period | Concentration (μg/m3) | Reference |
|---|---|---|---|---|
| Japan | University | March 2001 | 164‐1086 |
|
| Japan | University | Summer 2002 | 25‐1183 |
|
| Sweden | Office building | Not reported | 1000 (max) |
|
| Japan | Nondomestic buildings | June 2002‐October 2004 | 16.5 (geometric mean) |
|
| USA | Office building | Summer 1995 | 0.3‐48 |
|
| Winter 1997‐1998 | ||||
| USA | Houses | 1997‐1998 | <7.95 |
|
| Japan | Large‐scale buildings | 2003‐2007 | 13.5 (geometric mean) |
|
| Japan | University | August‐September 2003 | 132 (max) |
|
| Japan | School | August 2007 | 12‐302 |
|
| Japan | Shopping center | June 2006 | 69.2 (max), 6.2 (geometric mean) |
|
| Japan | Museums | September and October 2005 | 1.30 (max) |
|
| Japan | Dwellings | October 2013 and January 2014 | 5.1 (max) |
|
| Sweden | Residential buildings | Not reported | 1‐86 |
|
| West Germany | Dwellings | Not reported | 2 (average) |
|
| Japan | Large‐scale buildings | July 2004‐September 2007 | Summer 55.4, winter 13.7 (geometric mean) |
|
| Switzerland | University | January and June 2000 | 4‐17 |
|
| Europe | Buildings | Summer 2012‐winter 2013 | Summer 4.7, winter 3.9 (average) |
|
| Finland | Office building | December 2000‐March 2001 | ca. 100 |
|
| Sweden | Buildings | Not reported | 17 (max), 9.8 (average) |
|
| Sweden | Rehabilitation center | Not reported | 0.3‐0.6 |
|
| Japan | Temporally houses | June 2011 | 69 ± 12.8 |
|
| Sweden | Hospitals | November 1996‐January 1997 | 4.8‐19.8 |
|
| Sweden | Hospitals | January‐February 1997 | 5‐20 |
|
| Sweden | Hospitals | January‐February 1997 | 2‐32 |
|
Summary of effects on human health
| Country | Location | Symptoms | Concentration (μg/m3) | Reference |
|---|---|---|---|---|
| Sweden | Hospital | Nasal and ocular symptoms | 5‐20 |
|
| Sweden | Hospital | Asthma symptoms | 2‐32 |
|
| Sweden | Building | Nasal mucosal inflammation | 9.8 (average), 17 (max) |
|
| Japan | University | Coughing, throat irritation, and sore eyes | 164‐1086 |
|
| Japan | University | Problems with the nasal passages, throat, and lower airways | 25‐1183 |
|
| Finland | Office building | Respiratory, conjunctival, and dermal symptoms; adult‐onset asthma was approximately nine times higher | Mean 2 (range 1‐3) |
|
| Finland | School | Irritation symptoms in the respiratory tract and eyes | 1‐4 |
|
| Sweden | Rehabilitation center | Ocular, nasal, and respiratory symptoms | 0.3‐0.6 |
|
| Japan | University | Ocular pain and headache | 37.1‐62.1 |
|
| Switzerland | University | Sickness and headache | 4‐17 |
|
Summary of inhalation and oral exposure
| Concentration/dose | Period | Exposure | Species | Effects | Reference |
|---|---|---|---|---|---|
| 227 ppm | 6 h | Inhalation | Mouse, rat, and guinea pig | Mucous irritation in the eyes, nose, throat, and respiratory passages |
|
| 0, 15, 40, 120 ppm | 90 d | 6 h/d Inhalation | Rat | NOAEL of 120 ppm |
|
| 0, 20, 60, 150 ppm | 3 mo | 8 h/d Inhalation | Mouse | Inflammation and degeneration of the olfactory epithelium at ≥20 ppm |
|
| 100 mg/kg | Single | Intragastric administration | Rat | No direct effect on protein kinase C activity |
|
| 3.8 mmol/kg/d | 3 d | Gastric intubation | Rat | Increased cytochrome P450 4A1 levels |
|
| 2% (20 mg/kg/d) | 3 wk | In food | Rat | Significant decreases in triglyceride and cholesterol serum levels |
|
| 88 g/d/hen | Single | In food | Hen | Lowered plasma level of free cholesterols, reduced liver fats |
|
| 833 mg/kg/d | 3 wk | Gastric intubation | Rat | Increased liver weight |
|
| 4 mmol/kg/d (520.8 mg/kg/d) | 7 d | Gavage | Rat | Increases in both wet liver weight and antipyrine clearance |
|
| 1000 mg/kg/d | 3 wk | Gavage | Rat | Thirty percent increase in liver‐to‐body weight ratio; increase in peroxisome cell fraction and in peroxisome density |
|
| 130 mg/kg/d | 14 d | Gavage | Rat | Not induce hepatomegaly, peroxisome proliferation, and hyperlipidemia |
|
| 0‐1.75 g/kg/d | 14 d | Gavage | Mouse, rat | Increases in relative liver weights and peroxisomal β‐oxidation |
|
| 0, 25, 125, 250, 500 mg/kg/d (5 consecutive days/wk) | 13 wk | Gavage | Mouse, rat | Reduced body weight gain and increased relative liver, kidney, stomach, and testes weights at 500 mg/kg/d |
|
| NOEL of 125 mg/kg/d | |||||
| 0, 50, 200, 750 mg/kg/d (5 consecutive days/wk) | 18 mo | Gavage | Mouse, rat | Reduced body weight gain and increased relative liver and stomach weights at 500 mg/kg/d |
|
| 0, 50, 150, 500 mg/kg/d (5 consecutive days/wk) | 24 mo | Gavage | Rat | Decrease in body weight gain and dose‐dependent increases in relative liver, stomach, brain, kidney, and testis weights at 150 mg/kg/d and 500 mg/kg/d |
|
Summary of the in vitro studies
| Experimental conditions | Effects | Reference |
|---|---|---|
| The mitochondrial fraction of rat liver was treated with 1% 2EH | Low inhibitory effect on the state 3 respiration |
|
| Adult rat hepatocytes were cultured for 48 h in the presence of 0.2 and 1 mmol/L 2EH | Increased numbers of peroxisomes |
|
| Increased activities of carnitine acetyltransferase and 7‐ethoxycoumarin | ||
| Primary rat hepatocytes were cultured with 0‐0.5 mmol/L 2EH for 72 h | No effect on CN‐‐insensitive palmitoyl‐CoA oxidation |
|
| Cells of mice, rats, guinea pigs, and marmosets were cultured with 0.5 mmol/L 2EH for 72 h | Increased cyanide‐insensitive fatty acyl CoA oxidase activity in mice and rats |
|
| Rat Kupffer cells were cultured with 1.25‐3 mmol/L 2EH for 3 d | Increased intracellular calcium level at 3 mmol/L |
|
| Rat Kupffer cells were treated with 0.9 mmol/L 2EH | No effect on superoxide production |
|
| The cytosol of mouse and rat liver was treated with 15 mmol/L 2EH | Cytosolic GST was three times more potent in the mice than in the rats |
|
| Mouse liver was incubated with 0.25‐1.00 mmol/L 2EH | Significant inhibition of ADH activity but no appreciable effect on ALDH activity |
|
| Rat liver was incubated with 2.5‐15.0 mmol/L 2EH | Significant inhibition of the activities of aminopyrine N‐demethylase and aniline hydroxylase |
|
| Mice spleen cells were incubated with 10−8‐10−3 mol/L 2EH for 24 h | IL‐2 was induced in CD4 cells, but not in CD8 cells |
|
| Mice trigeminal ganglia neurons cells were incubated with 1‐10 mmol/L 2EH | Activation expressed TRPA1 in a concentration‐dependent manner |
|
| Perfused rat liver was incubated with 0.1‐3 mmol/L 2EH | Extensive cell damage due to lactose dehydrogenase leakage |
|
| Perfused rat liver was incubated with 200 µmol/L 2EH | The rate of ketone body production was decreased to about 60% |
|
| Mitochondria isolated from perfused rat livers were treated with 70 µmol/L and 3 mmol/L 2EH | Inhibition of the oxygen uptake in the periportal regions, but not in the centrilobular regions |
|